Exact Sciences Precision Oncology

Have you checked out the new Exact Sciences Provider Hub? It’s easier than ever to order #oncology tests, specify billing details and retrieval methods, catalog clinical information, and even share the report with other providers—all at the click of a mouse. #Healthcare #GenomicProfiling #CancerCare #PrecisionMedicine

Announcing a newly streamlined Exact Sciences Provider Hub. Now, when you log in to manage #oncology tests you’ll find a better ordering experience, easier result tracking, quick onboarding—and tech support right at your fingertips. https://lnkd.in/ewz9E3GV #Healthcare #GenomicProfiling #PrecisionMedicine

When selecting therapies for patients with #advancedcancer, a personalized approach is crucial. Rick Baehner, MD, discusses the importance of next-generation sequencing (NGS) technologies, like the OncoExTra® test, during therapy selection in the new Medical Device Network article, "NGS: the road to personalising cancer care." Read the full article: https://bit.ly/3XJGhch

The OncoExTra® test provides clinically actionable insights for patients with #advancedcancer in an easy-to-interpret report, analyzing nearly 20K genes with patient-matched tumor-normal sequencing. Learn More: https://lnkd.in/gCvU57my #Oncology #GenomicProfiling #CancerCare

The OncoExTra® test provides ultra-comprehensive genomic profiling for patients with #advancedcancer in an easy-to-interpret report, analyzing nearly 20K genes with patient-matched tumor-normal sequencing. Learn More: https://lnkd.in/gAhUfU3k #Oncology #GenomicProfiling #CancerCare

We’re excited to attend The 2024 ASCO® Annual Meeting in Chicago! Join us to learn how our highly intelligent tests provide actionable, personalized results at every stage of cancer care. Learn more: https://bit.ly/4aN5RAC #ASCO24 #ASCO2024 #AmericanSocietyofClinicalOncology #Cancer #Oncology #Chemotherapy #PrecisionOncology #PrecisionMedicine #CancerResearch #CancerTesting

Join us at The 2024 ASCO® Annual Meeting in Chicago to learn about our growing portfolio of screening and genomic tests for oncology, including: • The Oncotype DX Breast Recurrence Score® test for early-stage HR+, HER2- breast cancer • The Riskguard™ test for evaluating hereditary cancer risk • The OncoExTra® test for advanced-stage cancer therapy selection Learn more: https://bit.ly/4aN5RAC #ASCO24 #ASCO2024 #AmericanSocietyofClinicalOncology #Cancer #Oncology #Chemotherapy #PrecisionOncology #PrecisionMedicine #CancerResearch #CancerTesting

Every #cancer patient is different, which means every tumor is different. With the #genomic and #genetic insights from #PrecisionOncology tests, it’s easier than ever to help inform decisions with actionable data customized to each patient’s situation. Learn More: https://lnkd.in/eCr8cPfc

For your patients with early-stage HR+, HER2- #breastcancer, choose a test that’s recognized by major breast cancer guidelines: the Oncotype DX Breast Recurrence Score® test. Learn more: https://lnkd.in/exp-M--5 #PrecisionOncology #OncotypeDX #Oncology